Skip to content

Exploratory study of urinary shedding products as a novel biomarker for lung small cell carcinoma

Exploratory study of urinary shedding products as a novel biomarker for lung small cell carcinoma - A urinary biomarker for lung small cell carcinoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000030841
Enrollment
100
Registered
2018-01-18
Start date
2018-01-22
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small cell lung carcinoma

Interventions

None listed

Sponsors

University of Miyazaki
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with small cell lung carcinoma 1.Patients aged equal to or greater than 20 years-old. 2.Patients diagnosed primary lung cancer. 3.Patients diagnosed small cell lung carcinoma by cytology or histology(2015 WHO Classification of Lung Tumors). 4.Previously untreated patients with small cell lung carcinoma. 5.Patients who had a detailed briefing of the trial prior to the enrollment and voluntarily signed a consent form. Healthy controls 1.Those who age are equal to or greater than 20 years-old at the time of obtaining informed consent. 2.Those who have no abnormal findings in chest X-ray, blood glucose levels, serum lipids, serum liver function, serum renal function, and urinalysis within one year of obtaining informed consent. 3.Those who do not receive any regular prescription. 4.Those who are never smokers. 5.Those who had a detailed briefing of the trial prior to the enrollment and voluntarily signed a consent form.

Exclusion criteria

Exclusion criteria: Patients with small cell lung carcinoma 1.Patients who has been already received any treatments for small cell lung carcinoma. 2.Patients who have proteinuria, positive urine sugar or urine occult blood in urinalysis. 3.Patients who have renal dysfunction (Serum levels of creatinine > 2.0 mg/dl). 4.Patients who have current malignant neoplasm other than small cell lung carcinoma, or past history of malignant neoplasm within 5 years. 5.Patients who have alcohol or drug dependence or who are suspected to have alcohol or drug dependence. 6.Patients who is pregnant or who is suspected to be pregnant. 7.Patients who attending physicians consider to be inappropriate for this study. Healthy controls 1.Those who have proteinuria, positive urine sugar or urine occult blood in urinalysis. 2.Those who have past history of malignant neoplasm within 5 years. 3.Those who have alcohol or drug dependence or who are suspected to have alcohol or drug dependence. 4.Those who are pregnant or who are suspected to be pregnant. 5.Those who were enrolled another clinical trial and were prescribed a study drug within one month. 6.Those who are current smokers or ex-smokers. 7.Those whose attending physicians consider to be inappropriate for this study.

Design outcomes

Primary

MeasureTime frame
Detection of candidates for a diagnostic urinary biomarker of small cell lung carcinoma

Secondary

MeasureTime frame
1.Sensitivity, specificity, positive likelihood ratio and negative likelihood ratio of the detected biomarkers. 2.Confirmation of the protein fragments, pre-fragmented proteins and cleaving enzymes in tissue and blood samples. 3.Relationship between the detected biomarkers and prognosis. 4.Relationship between the detected biomarkers and presence of metastasis.

Countries

Japan

Contacts

Public ContactNobuhiro Matsumoto

University of Miyazaki Neurology, Respirology, Endocrinology and Metabolism, Internal Medicine, Faculty of Medicine

nobuhiro@med.miyazaki-u.ac.jp0985-85-2965

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026